Sugi Predict

Sugi Predict / Compounds / SCHEMBL1978696

SCHEMBL1978696

SCHEMBL1978696

C=C(C(=O)OCC)c1c(OCOC)cccc1OCOC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 2/20 0.43
▸ MAPT P10636 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ PLIN1 O60240 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ PLIN5 Q00G26 1/20 0.40
▸ ABHD5 Q8WTS1 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ TSHR P16473 1/20 0.38
▸ GPR35 Q9HC97 1/20 0.36
▸ CASP1 P29466 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27737306 0.90 MAPT (0.44) MAPTALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL17188975 0.85 PPARA (0.39) PTPN1MAPTALDH1A1MEN1KMT2A
SCHEMBL1979914 0.85 PTPN1 (0.46) PTPN1MAPTALDH1A1MEN1KMT2A
SCHEMBL1735896 0.84 MAPT (0.51) MAPTALDH1A1MEN1KMT2APLIN1
SCHEMBL9901466 0.83 PTPN1 (0.43) PTPN1MAPTALDH1A1MEN1KMT2A
SCHEMBL31690566 0.83 PTPN1 (0.43) PTPN1MAPTALDH1A1MEN1KMT2A
SCHEMBL19376299 0.83 PTPN1 (0.46) PTPN1MAPTALDH1A1MEN1KMT2A
SCHEMBL9900844 0.82 BACE1 (0.35) PTPN1MAPTALDH1A1MEN1KMT2A
SCHEMBL27737184 0.80 CA12 (0.48) PTPN1MAPTALDH1A1MEN1KMT2A
SCHEMBL27737210 0.79 MAPT (0.40) PTPN1MAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 — — US disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 — — US disclosed
EP-3390394-B1 HYDANTOIN MODULATORS OF KV3 CHANNELS AUTIFONY THERAPEUTICS LTD (GB) 2022-05-25 — — EP disclosed
EP-3390394-B1 HYDANTOIN MODULATORS OF KV3 CHANNELS AUTIFONY THERAPEUTICS LTD (GB) 2022-05-25 — — EP disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 — — US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 — — US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 — — US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 — — US disclosed
US-20200377485-A1 HYDANTOIN MODULATORS OF KV3 CHANNELS AUTIFONY THERAPEUTICS LTD (GB) 2020-12-03 — — US disclosed
US-20200377485-A1 HYDANTOIN MODULATORS OF KV3 CHANNELS AUTIFONY THERAPEUTICS LTD (GB) 2020-12-03 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 PTPN1 3807/4885MAPT 3926/4885ALDH1A1 1966/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 PTPN1 3807/4885MAPT 3926/4885ALDH1A1 1966/4885
US-20200377485-A1 HYDANTOIN MODULATORS OF KV3 CHANNELS KCNA3, KCNN3, KCND3 PTPN1 3783/4885MAPT 3209/4885ALDH1A1 2103/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 PTPN1 4193/4885MAPT 3789/4885ALDH1A1 462/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 PTPN1 4031/4885MAPT 3971/4885ALDH1A1 1789/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 PTPN1 3807/4885MAPT 3926/4885ALDH1A1 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.